View:
United States securities and exchange commission logo
April 7, 2023
John Umstead
Chief Financial Officer
G1 Therapeutics, Inc.
700 Park Offices Drive, Suite 200
Research Triangle Park, North Carolina 27709
Re: G1 Therapeutics,
Inc.
Form 10-K for the
Fiscal Year Ended December 31, 2022
Filed March 1, 2023
File No. 001-38096
Dear John Umstead:
We have limited our review of your filing to the financial
statements and related
disclosures and have the following comment. In our comment, we may ask
you to provide us
with information so we may better understand your disclosure.
Please respond to the comment within ten business days by
providing the requested
information or advise us as soon as possible when you will respond. If
you do not believe our
comment applies to your facts and circumstances, please tell us why in
your response.
After reviewing your
response to the comment, we may have additional comments.
Form 10-K for the Fiscal Year Ended December 31, 2022
Exhibits
Exhibit 23.1 Consent of PricewaterhouseCoopers LLP, page 112
1. Please amend your
filing to include a signed consent from PricewaterhouseCoopers LLP.
John Umstead
FirstName LastName
G1 Therapeutics, Inc. John Umstead
Comapany
April NameG1 Therapeutics, Inc.
7, 2023
April 27, 2023 Page 2
Page
FirstName LastName
In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.
You may contact Frank Wyman at 202-551-3660 or Mary Mast at 202-551-3613
with
any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences